uniQure Announces Closing of its Public Offering
(Thomson Reuters ONE) -
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 27, 2017 (GLOBE NEWSWIRE)
-- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe unmet medical needs, such as
hemophilia B, Huntington's disease and congestive heart failure, today announced
the closing of its underwritten public offering of 5,000,000 of its ordinary
shares at a public offering price of $18.25 per share. The gross proceeds to
uniQure from the offering, before deducting the underwriting discounts and
commissions and estimated offering expenses payable by uniQure, were
approximately $91,250,000. All ordinary shares sold in the offering were sold by
uniQure. In addition, uniQure has granted to the underwriters a 30-day option to
purchase up to 750,000 additional ordinary shares at the public offering price,
less underwriting discounts and commissions.
Leerink Partners and Evercore ISI acted as the joint book-running managers for
the offering. Chardan acted as lead manager and H.C. Wainwright & Co. acted as
co-manager for the offering.
The securities described above were offered by uniQure pursuant to its shelf
registration statement on Form S-3 (File No. 333-216701) filed with the
Securities Exchange Commission (the "SEC") on March 15, 2017, as amended on May
15, 2017 and declared effective by the SEC on May 26, 2017. A final prospectus
supplement and accompanying prospectus relating to the offering have been filed
with the SEC and are available on the SEC's website, located at www.sec.gov.
Copies of the final prospectus supplement and the accompanying prospectus
relating to the offering may be obtained from Leerink Partners LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by
telephone at (800) 808-7525 ext. 6132 or by email at Syndicate(at)Leerink.com; and
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
36th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email
at ecm.prospectus(at)evercore.com.
This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these
securities, in any state or other jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or other jurisdiction.
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with
potentially curative results. We are leveraging our modular and validated gene
therapy technology platform to advance a pipeline of proprietary and partnered
gene therapies to treat patients with hemophilia, Huntington's disease and
cardiovascular diseases.
uniQure Contacts
For Investors:
Maria Cantor
Direct : +339-970-7536
Mobile: 617-680-9452
m.cantor(at)uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 70
e.mulder(at)uniQure.com
For Media:
Tom Malone
Direct: 339-970-7758
Mobile: 339-223-8541
t.malone(at)uniqure.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via GlobeNewswire
Datum: 27.10.2017 - 22:03 Uhr
Sprache: Deutsch
News-ID 565659
Anzahl Zeichen: 3974
contact information:
Town:
Amsterdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 319 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"uniQure Announces Closing of its Public Offering"
steht unter der journalistisch-redaktionellen Verantwortung von
uniQure N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
